Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

Table 2

Adverse events occurring in more than 1 patient and all grade 3-4 adverse events.

Adverse event	Grade 2	Grade 3	Grade 4
Anemia	17	7	1
Neutropenia	7	7	6
Leukopenia	6	8	3
Hyperglycemia	12	3	1
Hypoalbuminemia	13	1
Lymphopenia		11	2
Thrombocytopenia	1	4	5
Elevated ALT	9		1
Elevated AST	7	1
Fatigue	1	5
Hypophosphatemia	2	3
Elevated alkaline phosphatase	2	2
Hypokalemia		2
Edema		2
Diverticulitis		1
Kidney stone		1
Cellulitis		1
Neck pain		1
Pneumonia		1
Mucositis	3
Hemorrhage, nose	1
Perforation, GI-small bowel NOS	1
Thrombosis/thrombus/embolism			1